A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing
Sreenivasa Nattam, MD
Advertisement
Articles by Sreenivasa Nattam, MD
Advertisement
Latest Updated Articles
- Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
February 1st 2001
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
4
The Intersection of Technology and Psycho-Oncology Care
5